Companies › Fore Biotherapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| plixorafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 2 | Cancer Harboring BRAF Alterations | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05503797 | plixorafenib | Phase 2 | Cancer Harboring BRAF Alterations | Oncology | Dec 2027 |
Roche Pfizer Pierre Fabre Medicament Novartis Haisco Pharmaceutical Group Erasca Shanghai Kechow Pharma Day One Biopharmaceuticals Ipsen Hanmi Pharmaceutical Company
NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.